Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

iMSC-mediated delivery of ACVR2B-Fc fusion protein reduces heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva.

Stem cell research & therapy - 18 Mar 2024

Gao Pan, Inada Yoshiko, Hotta Akitsu, Sakurai Hidetoshi, Ikeya Makoto

Abstract excerpt

BACKGROUND: Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disease caused by a gain-of-function mutation in ACVR1, which is a bone morphogenetic protein (BMP) type I receptor. Moreover, it causes progressive heterotopic ossification (HO) in connective tissues. Using FOP patient-derived induced pluripotent stem cells (FOP-iPSCs) and mouse models, we elucidated the underlying mechanisms of FOP...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Activin Receptors, Type II
Share to Bone Morphogenetic Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Transgenic

Share to Mutation

Share to Myositis Ossificans

Share to Ossification, Heterotopic

Share to Signal Transduction

Source

Open in PubMed Open full text

Identifiers

PMID: 38500216
DOI: 10.1186/s13287-024-03691-7
PMCID: PMC10949803

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

iMSC-mediated delivery of ACVR2B-Fc fusion protein reduces heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva.PMID 38500216Read ↗

Anti-ACVR1 antibodies exacerbate heterotopic ossification in fibrodysplasia ossificans progressiva (FOP) by activating FOP-mutant ACVR1.Semantic proximity Read ↗

An anti-ACVR1 antibody exacerbates heterotopic ossification by fibro/adipogenic progenitors in fibrodysplasia ossificans progressiva miceSemantic proximity Read ↗

Fibrodysplasia ossificans progressiva.Semantic proximity Read ↗

An anti-ACVR1 antibody exacerbates heterotopic ossification by fibro-adipogenic progenitors in fibrodysplasia ossificans progressiva mice.Semantic proximity Read ↗

How Activin A Became a Therapeutic Target in Fibrodysplasia Ossificans ProgressivaSemantic proximity Read ↗

Generation of an induced pluripotent stem cell line (TRNDi012-B) from Fibrodysplasia Ossificans Progressiva (FOP) patient carrying a heterozygous mutation c. 617G > A in the ACVR1 gene.Semantic proximity Read ↗

Novel Therapeutic Targets for Fibrodysplasia Ossificans Progressiva: Emerging Strategies and Future DirectionsSemantic proximity Read ↗

An mTOR Signaling Modulator Suppressed Heterotopic Ossification of Fibrodysplasia Ossificans ProgressivaSemantic proximity Read ↗

From mysteries to medicines: drug development for fibrodysplasia ossificans progressivaSemantic proximity Read ↗

The Horizon of a Therapy for Rare Genetic Diseases: A “Druggable” Future for Fibrodysplasia Ossificans ProgressivaSemantic proximity Read ↗

Twists in the fibrodysplasia ossificans progressiva story challenge and expand our understanding of BMP biology.Semantic proximity Read ↗

Activin-dependent signaling in fibro/adipogenic progenitors causes fibrodysplasia ossificans progressivaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.